Pharmacologic IRE1 Activation Rewires Cholesterol Metabolism to Suppress TH17 Differentiation
T helper 17 (TH17) cells are a subset of CD4 T cells that coordinate immune responses against extracellular bacterial and fungal pathogens. Dysregulation of TH17 cell responses drives excessive inflammation and contributes to the development of chronic inflammatory and autoimmune diseases, including psoriasis, inflammatory bowel disease, and multiple sclerosis. Here, we demonstrate that…
Th17 cells, a type of CD4 T helper cells, play a crucial role in combating extracellular bacterial and fungal infections. However, when their response is not regulated properly, it can lead to chronic inflammation and autoimmune disorders such as psoriasis, inflammatory bowel disease, and multiple sclerosis. Researchers have now discovered that activating the IRE1 signaling pathway in the unfolded protein response (UPR) can specifically prevent the development of Th17 cells without affecting other helper T cell subsets.
By stimulating IRE1, scientists found that this process reduces the formation of Th17 cells, maintaining the balance of different helper T cell types. This activation works by curbing the accumulation of cholesterol within the cells that are differentiating into Th17 cells. Cholesterol is a key component in the development of Th17 cells, and its regulation is vital for maintaining immune system balance.
The study reveals that IRE1 acts as a metabolic checkpoint, controlling cholesterol biosynthesis in differentiating Th17 cells. By pharmacologically activating IRE1, researchers have successfully inhibited the development of Th17 cells, offering a promising therapeutic approach to manage diseases driven by excessive Th17 cell activity.
Rewritten by urgent.news; may contain errors — check the original.